MedPath

Role of MgSO4 in reducing dose requirement of PROPOFOL during Neurosurgical procedure.

Not Applicable
Conditions
Health Condition 1: null- ASA1 & ASA2
Registration Number
CTRI/2018/12/016673
Lead Sponsor
Department of anaesthesiology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

pt undergoing elective neurosurgery

ASA1 and ASA2

Exclusion Criteria

allergy to mgso4 or any other study drug,

pt taking any enzyme inducer or inhibitor drug,

pt refusal,

renal,hepatic or cardiovascular dysfunction,

atrioventricular conductance disturbances,

opioid or analgesic abuse,

pt on chronic treatment with CCB or Magnesium.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
total dose of propofol required during elective neurosurgeryTimepoint: 1,5,10,15,30,45,60,90,120 mins and at the end of surgery
Secondary Outcome Measures
NameTimeMethod
heart rate, SBP, DBP, MAP. SpO2, EtCO2, BIS,TOFTimepoint: 1,5,10,15,30,45,60,90,120 mins and at the end of surgery
© Copyright 2025. All Rights Reserved by MedPath